LMNL Liminal BioSciences Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

LMNL [NASD]

Liminal BioSciences Inc.

Healthcare | Biotechnology | Canada

statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	71.39%	Shs Outstand	23.39M	Perf Week	13.49%
Market Cap	566.78M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.90M	Perf Month	43.82%
Income	-	PEG	-	EPS next Q	-	Inst Own	14.23%	Short Float	0.22%	Perf Quarter	139.77%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.12	Perf Half Y	84.18%
Book/sh	3.36	P/B	5.51	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-48.58%
Cash/sh	1.20	P/C	15.49	EPS next 5Y	-	ROE	-	52W Range	5.25 - 31.45	Perf YTD	120.88%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-41.14%	Beta	1.81
Dividend %	-	Quick Ratio	2.40	Sales past 5Y	-	Gross Margin	-	52W Low	252.57%	ATR	3.41
Employees	300	Current Ratio	2.70	Sales Q/Q	-52.20%	Oper. Margin	-	RSI (14)	57.95	Volatility	19.00% 16.25%
Optionable	No	Debt/Eq	0.58	EPS Q/Q	96.50%	Profit Margin	-	Rel Volume	0.23	Prev Close	18.09
Shortable	Yes	LT Debt/Eq	0.49	Earnings	-	Payout	-	Avg Volume	129.53K	Price	18.51
Recom	-	SMA20	32.41%	SMA50	50.19%	SMA200	99.40%	Volume	29,411	Change	2.32%

Aug-06-20 05:01PM	Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference PR Newswire
Jul-22-20 07:55AM	Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange CNW Group -6.42%
Jul-17-20 08:00AM	Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases PR Newswire
Jul-02-20 11:16AM	Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy CNW Group -26.50%
Jun-30-20 05:31PM	Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors PR Newswire
05:31PM	Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors CNW Group
05:00PM	Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020 PR Newswire
Jun-11-20 05:00PM	Liminal BioSciences to Present at Raymond James Human Health Innovation Conference CNW Group -8.72%
Jun-09-20 03:53PM	Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM) PR Newswire
03:53PM	Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM) CNW Group
May-28-20 05:30PM	Liminal BioSciences to present at Jefferies Virtual Healthcare Conference CNW Group -9.51%
May-22-20 07:14AM	Investors Who Bought Liminal BioSciences (TSE:LMNL) Shares Five Years Ago Are Now Down 100% Simply Wall St.
May-13-20 05:00PM	Liminal Biosciences Reports Q1 2020 Results PR Newswire +6.02%
Mar-23-20 06:30AM	Liminal BioSciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-22-20 03:23PM	Liminal BioSciences comments on Coronavirus (COVID-19) PR Newswire
03:23PM	Liminal BioSciences comments on Coronavirus (COVID-19) CNW Group
Mar-20-20 05:01PM	Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results PR Newswire +9.60%
05:01PM	Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results CNW Group
05:00PM	Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast PR Newswire
Feb-12-20 07:30AM	Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia PR Newswire
07:30AM	Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia CNW Group
Feb-06-20 07:30AM	Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference CNW Group
Jan-13-20 07:00AM	Liminal BioSciences Outlines Corporate Priorities for 2020 PR Newswire -11.52%
07:00AM	Liminal BioSciences Outlines Corporate Priorities for 2020 CNW Group
Dec-23-19 03:43PM	Liminal BioSciences Comments on Unusual Market Activity CNW Group +81.85%
Nov-28-19 04:40PM	AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019 PR Newswire
04:40PM	AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019 CNW Group
Nov-27-19 07:30AM	Liminal BioSciences to Present at Piper Jaffray Healthcare Conference CNW Group
Nov-25-19 12:03PM	Liminal BioSciences announces closing of divestiture of bioseparations division to KKR CNW Group
Nov-18-19 07:30AM	Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement PR Newswire +16.15%

Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alstrom syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. Liminal BioSciences has partnership with CoVIg plasma alliance for the development of COVID-19 therapy. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience